Medicinal Chemistry of Neglected and Tropical Diseases: Advances in the Design and Synthesis of Antimicrobial Agents consolidates and describes modern drug discovery and development approaches currently employed to identify effective chemotherapeutic agents for the treatment of Neglected Tropical Diseases (NTDs) from a medicinal chemistry perspective. Chapters are designed to cater to the needs of medicinal chemists who work with chemotherapeutic developments for NTDs, as well as serve as a guide to budding medicinal chemists who wish to work in this area. It will introduce rational drug design approaches adopted in designing chemotherapeutics and validated targets available for the purpose.
Table of Contents
Key Concepts in Assay Development, Screening and the Properties of Lead and Development Candidate Compounds. The Application of Fragment-based Approaches to the Discovery of Drugs for Neglected Tropical Diseases. Chemical Hybridization Approaches Applied to Natural and Synthetic Compounds for the Discovery of Drugs Active Against Neglected Tropical Diseases. Current Inhibitors of Dengue Virus: An Overview. Overview of Drugs Used Against Zika Virus. Chikungunya Virus Infection: A Review on its Control and Treatment. Recent Advances in Repositioning Non-Antibiotics against Tuberculosis and Other Neglected Tropical Diseases. Prospects of Pre-clinical [6.6.0] Bicyclic Nitrogen Heterocycles in the Treatment of Tuberculosis. Progress in Antimalarial Drug Discovery and Development. Hits and Lead Discovery in the Identification of New Drugs against the Trypanosomatidic Infections. New Chemical Scaffolds to Selectively Target the Trypanothione Metabolism. The Renewal of Interest in Nitroaromatic Drugs: Towards New Anti-Kinetoplastid Agents. New Biological Targets for the Treatment of Leishmaniasis. Curcumin and Neglected Infectious Diseases. An Overview of Helminthiasis: Current State and Future Directions.
Dr. Venkatesan Jayaprakash graduated (B. Pharmacy) from Madras Medical College, Madras in Pharmaceutical Sciences. He did his post graduation (M. Pharmacy) in Pharmaceutical Chemistry from Banaras Hindu University, Varanasi. He received his Ph.D. from Birla Institute of Technology, Mesra. Since 2004, he is working as a faculty member in Department of Pharmaceutical Sciences and Technology, Birla Institute of Technology, Mesra. He is medicinal chemist working in the area of drug design and development against therapeutically validated targets. His current research interest is on developing new chemical entities for the treatment of Tuberculosis (Mycobactin synthetase inhibitors), Viral infections (protease and methyltransferase inhibitors), Cancer (CYP-1A & 1B and Cdk-4 inhibitors) and Depression (MAO inhibitors).
Dr. Daniele Castagnolo is Lecturer of Pharmaceutical Chemistry at the Institute of Pharmaceutical Science at King’s College London. Dr. Castagnolo’s research interests range widely from organic synthetic chemistry to medicinal chemistry and are mainly focused on the design and discovery of bioactive molecules active against Mycobacterium tuberculosis, drug-resistant Gram+/- bacteria and viruses. In addition, Dr. Castagnolo’s research group is interested in the development of novel biocatalytic and chemoenzymatic methods for the manufacturing of druglike compounds.
Prof. Yusuf Özkay works in the Anadolu University, Faculty of Pharmacy, Department of Pharmaceutical Chemistry, Eskişehir-Turkey. Synthesis and biological evaluation of new enzyme inhibitors, central nervous system related compounds, anticancer, and antimicrobial agents constitute his main research areas. He has more than 50 articles in the journals covered by Science Citation Index, over 100 presentations in the international congresses, and more than 500 citations made to the works of him.